Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3137 USD | +2.62% | +29.04% | -82.76% |
04-15 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
04-12 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
Valuation
Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 87.68 | 53.78 | 6.206 | - | - |
Enterprise Value (EV) 1 | 87.68 | 53.78 | 6.206 | 6.206 | 6.206 |
P/E ratio | -5.09 x | -0.48 x | -0.12 x | -0.48 x | -0.6 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 13,345 | 17,404 | 19,784 | - | - |
Reference price 2 | 6.570 | 3.090 | 0.3137 | 0.3137 | 0.3137 |
Announcement Date | 22-08-01 | 23-07-31 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -15.59 | -16.58 | -19.35 | -16.42 | -18.42 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -14.82 | -122.5 | -62.39 | -16.22 | -18.22 |
Net income 1 | -16.87 | -104.6 | -51.84 | -16.22 | -18.22 |
Net margin | - | - | - | - | - |
EPS 2 | -1.290 | -6.490 | -2.720 | -0.6500 | -0.5200 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 22-08-01 | 23-07-31 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.33 | -4.169 | -4.496 | -4.087 | -3.653 | -4.759 | -4.076 | -4.997 | -5.93 | -4.025 | -4.4 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.38 | -4.089 | -4.046 | -4.177 | -3.638 | -5.302 | -109.4 | -6.071 | -6.072 | -48.88 | -4.35 |
Net income 1 | -2.975 | -3.512 | -7.317 | -1.729 | -0.949 | -7.485 | -94.45 | -5.919 | -5.158 | -39.37 | -4.35 |
Net margin | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2200 | -0.2600 | -0.5500 | -0.1300 | -0.0600 | -0.4400 | -6.000 | -0.3300 | -0.2900 | -1.880 | -0.2200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21-11-23 | 22-02-24 | 22-08-01 | 22-08-29 | 22-11-29 | 23-03-01 | 23-07-31 | 23-08-29 | 23-11-28 | 24-02-28 | - |
Balance Sheet Analysis
Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 22-08-01 | 23-07-31 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.76% | 6.05M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- PRTG Stock
- Financials Portage Biotech Inc.